Alan Fuhrman

Medisystems Corp. manufactures and distributes medical devices for dialysis and blood related treatments. Its products include Streamline and ReadySet blood tubing sets, MasterGuard and ButtonHole needle sets, safety accessories and access management tools. The company was founded on March 22, 1993 and is headquartered in Lawrence, MA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT.

Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX.